71 results about "Mitochondrial respiration" patented technology

The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other active agents. The present invention further relates to use of the compounds of the invention as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. More particularly the present invention relates to the use of the compounds of the invention in a method of treating and / or preventing cancers presenting tumor-initiating cells. (Formula I) (I)

The invention discloses an insecticidal and acaricidal composition comprising cyenopyrafen. The composition comprises the following synergistic compound active components: a component A selected from cyenopyrafen, and a component B selected from mitochondrial respiration inhibitor type insecticidal and acaricidal agents, growth and development inhibitor type insecticidal and acaricidal agents, neurotoxin type insecticidal and acaricidal agents, pyrethroid type insecticidal and acaricidal agents, macrolide type insecticidal and acaricidal agents, carbamate type insecticidal and acaricidal agents, etc. The insecticidal and acaricidal composition provided by the invention is especially suitable to be used for controlling phytophagous mites harming fruit trees, cotton, vegetables and ornamental plants.

The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.

Disclosed are fungicidal mixtures, compositions and methods for controlling plant diseases relating to combinations comprising (a) at least one compound selected from phenylamidines of Formula I, N-oxides, and agriculturally suitable salts thereof (I) wherein A is C3alkylene, optionally substituted with one or two methyl; W is CR5R6R7 or SiR8R9R10; and R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the disclosure; and (b) at least one compound selected from alkylenebis(dithiocarbamate) fungicides, compounds acting at the bc1 complex of the fungal mitochondrial respiratory electron transfer site, cymoxanil, compounds acting at the demethylase enzyme of the sterol biosynthesis pathway, morpholine and piperidine compounds that act on the sterol biosynthesis pathway, phenylamide fungicides, pyrimidinone fungicides, chlorothalonil, carboxamides acting at complex II of the fungal mitochondrial respiratory electron transfer site, quinoxyfen, metrafenone, cyflufenamid, cyprodinil, copper compounds, phthalimide fungicides, fosetyl-aluminum, benzimidazole fungicides, cyazofamid, fluazinam, iprovalicarb, propamocarb, validamycin, dichlorophenyl dicarboximide fungicides, zoxamide and dimethomorph, and their agriculturally suitable salts.

The invention discloses application of a glutaminase inhibitor in preparation of a medicine for treating psoriasis. In-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, including remarkably reducing the Baker score of skin lesion, effectively reducing the epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing the medicine for treating psoriasis.

The invention discloses a preparation for enhancing hypoxic tumor photodynamic therapy and a preparation method and application of the preparation, and belongs to the technical field of medicines. The preparation is a nano preparation formed by self-assembly of an active oxygen sensitive material and a photosensitive material, the active oxygen sensitive material is obtained by modifying a hydrophilic polymer material with a phenylboronic acid ester group, and the photosensitive material is obtained by modifying the hydrophilic polymer material with a photosensitizer. The preparation method comprises the following steps that a functional amphiphilic polymer, namely the active oxygen sensitive material and the photosensitive material is constructed, and then drugs capable of inhibiting mitochondrial respiration of cells are encapsulated by a self-assembly method to prepare the preparation. The preparation has good stability in tumor tissues and cells, and can quickly respond to stimulation to release the drugs when being stimulated by external light.

The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals whose inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production, the invention proposes to assist in weight loss by improving the inefficient production of energy by the respiratory transport chain of mitochondria. The invention is useful for the management of the metabolic syndrome, a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well as generally in the body is part of the benefit of the combination of liposomal reduced glutathione and 1-arginine.

The invention provides methods for screening for agents that modulate mitochondrial function and in particular mitochondrial regulation of intracellular calcium. The methods may be used to detect agents that bind to a mitochondrial calcium uniporter and may also detect inhibitors or uncouplers of mitochondrial respiration. Agents identified using the screens provided herein have application in the prevention and treatment of a variety of diseases associated with abnormal mitochondrial function.

A system and method for evaluating subjects using MRI and a contrast agent that overcomes the low sensitivity nature of previous detection methods is provided by using a 3D golden-angle-based radial sampling approach. In one configuration, direct detection of metabolic H217O generated from mitochondrial respiration may be imaged. Radial encoding allows for the use of ultra-short echo-time to compensate for signal loss due to the short T2 relaxation time of 17O and other contrast agents. In addition, the golden-ratio-based sampling scheme has the flexibility of enabling various undersampling schemes and retrospective selection of temporal resolution for dynamic imaging. A 3D radial sampling scheme may also give rise to additional SNR gain by further shortening the echo-time.

It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.

The current technology is related to methods for rapidly determining the metabolic baseline and potential of living cells. Embodiments relate to measuring the activity of each of the two major energy-generating pathways within the cell: mitochondrial respiration and glycolysis, first under baseline conditions, and again after applying a stress to the cells to demand increased energy supply. In some embodiments the stress may be applied by exposing the cells to a combination of two chemical compounds: a mitochondrial uncoupler and an ATP synthase inhibitor. In one embodiment, the metabolic energy generating activity of the mitochondrial respiration pathway is determined by measuring the rate of oxygen consumption by the living cells, and the metabolic energy generating activity of the glycolysis pathway is determined from a measurement of extracellular acidification caused by secretion of protons from the cell. Other embodiments are related to an apparatus for determining a metabolic potential of a cell sample in a well of a multiwell plate.

Compositions for controlling plant diseases caused by fungal plant pathogens are described, comprising: (a) a fungicidally effective amount of a compound of Formula I (including all geometric and stereoisomers, N -oxides, and agriculturally suitable salts thereof) wherein A, B, W, R 1 , R 2 , and R 3 are as defined in the disclosure; and (b) at least one compound selected from the group consisting of (b9) fosetyl-aluminum. Also disclosed are methods for controlling plant diseases caused by fungal plant pathogens that involves applying an effective amount of the combinations described.

The invention discloses a quick extraction method of high-activity mitochondria in plant organs and special extracting solution thereof. The quick extraction method comprises the following steps: mixing the plant organs, the extracting solution and grinding medium, homogenizing, collecting filtrate, carrying out differential centrifugal separation on the mitochondria in the plant organs, and thenadopting mitochondrial respiratory buffer solution for storage. The extracting solution is prepared from sucrose, sodium pyrophosphate, EDTA (Ethylene Diamine Tetraacetic Acid), potassium dihydrogen phosphate, BSA (Bovine Serum Albumin), cysteine, ascorbic acid and pvp-40. Proved by the experiment, the quick extraction method disclosed by the invention has the following advantages that the efficiency is high, i.e., the activity of the mitochondria is high; the applicability is wide, so that the quick extraction method can be applicable to extraction of the mitochondria of flower organs of multiple angiosperms; the storage time is long, and the activity can be maintained for 5 hours on an ice box, so that a great number of studies on the energy metabolism and the respiration of the mitochondria can be met; the operation is simple and the consumed time is short; the method provided by the invention lays a solid foundation for study on the respiratory chain and the energy metabolism of the mitochondria and has important practical application value.

The invention discloses a method for screening functional feed additives for piglets. The method for screening the functional feed additives for the piglets comprises the following steps: culturing porcine intestinal cells IPEC-1 in vitro; adding candidate nutrients from a culture medium of the porcine intestinal cells IPEC-1, and carrying out real-time observation on cell growth state and cell mitochondrial respiratory function indexes; screening the functional feed additives for the piglets from the candidate nutrients according to the cell growth state and the cell mitochondrial respiratoryfunction indexes. The invention aims at providing the method for screening the functional feed additives for the piglets by carrying out cell monitoring in real time and combining a cellular mitochondrial respiratory metabolism function as the assessment index.

This invention is related to a novel method of treating the chemotoxic effects on the central nervous system of chemotherapeutic drugs, namely Adriamycin, by administering a therapeutically effective amount of anti-Tumor Necrosis Factor-α antibody to a patient to alleviate the symptoms of the effects. The antibody operates to decrease the serum level of Tumor Necrosis Factor-α, prevents the p53 translocation to mitochondria and prevents the decline in mitochondrial respiration of brain tissues and thereby relieves the symptoms of somnolence caused by chemotherapeutic drugs.

Compositions for controlling plant diseases caused by fungal plant pathogens are described, comprising: (a) at least one compound of Formula I, including all geometric and stereoisomers, N-oxides and agriculturally suitable salts thereof: I—wherein R1, R2, R5 and R6, m and n are as defined in the disclosure; and (b) at least one compound selected from the group consisting of (b1) alkylenebis(dithiocarbamate) fungicides; (b2) compounds acting at the bc1 complex of the fungal mitochondrial respiratory electron transfer site; (b3) cymoxanil; (b4) compounds acting at the demethylase enzyme of the sterol biosynthesis pathway; (b5) morpholine and piperidine compounds that act on the sterol biosynthesis pathway; (b6) phenylamide fungicides; (b7) pyrimidinone fungicides; (b8) phthalimides; and (b9) fosetyl-aluminum. Also disclosed are methods for controlling plant diseases caused by fungal plant pathogens that involves applying an effective amount of the combinations described.

Compositions for controlling plant diseases caused by fungal plant pathogens are described, comprising: (a) at least one compound of Formula I, including all geometric and stereoisomers, N-oxides and agriculturally suitable salts thereof: (I) wherein R1, R2, R5 and R6, m and n are as defined in the disclosure, and (b) at least one compound selected from the group consisting of (b1) alkylenebis(dithiocarbamate) fungicides; (b2) compounds acting at the bc1 complex of the fungal mitochondrial respiratory electron transfer site, (b3) cymoxanil, (b4) compounds acting at the demethylase enzyme of the sterol biosynthesis pathway; (b5) morpholine and piperidine compounds that act on the sterol-biosynthesis pathway; (b6) phenylamide fungicides; (b7) pyrimidinone fungicides; (b8) phthalimides; and (b9) fosetyl-aluminum. Also disclosed are methods for controlling plant diseases caused by fungal plant pathogens that involves applying an effective amount of the combinations described. Also disclosed are certain novel compounds of Formula I.

The invention discloses a durable graphene antivirus antibacterial liquid and a preparation method thereof. The antibacterial liquid is prepared from the following raw materials in parts by weight: 3-8 parts of graphene oxide, 10-15 parts of an antibacterial synergist, 3.5-5 parts of sodium dodecyl benzene sulfonate, 3-5 parts of an emulsifier, 1-3 parts of glycerol, 1-3 parts of propylene glycol and 80-100 parts of water. The antibacterial synergist is prepared in the process of preparing the antibacterial liquid, the antibacterial synergist can act with a head group of acidic phospholipid in a bacterial cell membrane, so the infiltration capacity of the cell membrane is reduced, bacterial cell sap leaks, and bacterial cells die; meanwhile, the synergist can be combined with a Q0 site of cytochrome b in bacterial mitochondria, and electron transfer between the cytochrome b and the cytochrome c1 is blocked, so mitochondrial respiration is inhibited, mitochondria cannot supply energy required by normal metabolism of cells, and sterilization is more thorough.

The present invention relates to the characterization of mutants in the genes isp-1 and ctb-1, which are genes that have a function at the level of cellular physiology, mitochondrial respiration and electron transport, and resistance to oxidative stress, as well as regulating developmental, behavioral, reproductive and aging rates. Mutations in the genes isp-1 and ctb-1 are also provided. These genes and the protein they encode are used in a perspective of growth and aging control and in a therapeutic perspective for diseases in which mitochondrial function is altered. There is also provided methods of identification of compounds for the manipulation of the function of the isp-1 and ctb-1 genes and their protein products, as well as for the manipulation of the functions of mitochondria.

The invention relates to an immune cell treated by a magnetic field and application thereof. According to the invention, a medium static magnetic field with the intensity of 0.3T can promote secretionof CD8<+> T cell granzyme and cell factors of a mouse, increase the level of ATP and mitochondrial respiration and up-regulate expression of related genes Uqcrb and / or Ndefs 6 of a mitochondrial respiratory chain. In addition, magnetic receptor candidate genes Isca1 and Cry1 / Cry2 participate in regulation and control of expression of Uqcrb and / or Ndefs 6. An in-vivo experiment shows that the static magnetic field can inhibit growth and development of tumors by promoting secretion of the CD8<+>T cell granzyme and the cell factors. A killing ability test shows that static magnetic field treatment can enhance the killing ability of CD8<+> T cells, and the CD8<+> T cells treated by the magnetic field have a remarkable anti-tumor effect when being transfused back into a tumor grafted mouse.The invention not only discloses that the medium-intensity static magnetic field can enhance the killing ability of the CD8<+> T cells by promoting mitochondrial respiration, but also provides a novel method for enhancing the anti-tumor function of the CD8<+> T cells by a physical method.

The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and / or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.

The invention discloses an oxygen self-carrying nano photosensitive preparation as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation is prepared from an amphiphilic photosensitive polymer entrapped with a fluorocarbon compound with oxygen carrying capacity; the amphiphilic photosensitive polymer is a diblock copolymer modified by a photosensitizer, and the photosensitizer is selected from indocyanine green, a chlorin derivative, chlorophyll or heme; the fluorocarbon compound with the oxygen carrying capacity is selected from perfluorohexane, perfluoropentane, perfluorodecane, perfluorodecane or perfluorobromooctane. The oxygen self-carrying nano photosensitive preparation disclosed by the invention can obviously improve the oxygen level of a tumor by conveying oxygen to a tumor part, and enhances the killing effect of photodynamic; meanwhile, the preparation is combined with a cell mitochondrial respiration inhibitor, so that the hypoxia level of tumors can be further improved, and the treatment effect of photodynamic in a hypoxia area is remarkably improved.

Described is a method for cancer detection, progression analysis and malign tumour prognosis based on the study of metabolic markers of the cell. The method consists in using the study of the protein expression of the bioenergetic function of the mitochondrion, such as the beta-catalytic subunit of the H-ATP synthase, in relation to structural proteins and mitochondrial respiration, such as hsp 60 and cytochrome oxidase subunits I and IV respectively, and said mitochondrial bioenergetic index, (ratio of beta-ATPasa / hsp60; beta-ATPasa / COX I; beta-ATPasa / COX IV) which relates to the cellular protein expression of the glycolytic pathway, such as glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase M, in order to generate the bioenergetic index of the cell.

Disclosed are certain heterocyclic organic compounds that inhibit mitochondrial respiration and also lead to the maintenance of pluripotency of human embryonic stem cells in culture, even in the presence of oxygen. Exemplified are compounds, such as substituted 5-aminotetrazoles, which are reversible mitochondrial inhibitors. The pluripotency of the stem cells after culture is verified by the overexpression of pluripotent stem cell markers, exemplified by at least one of the genes NANOG, OCT4, and SURVIVIN after periods of culture in ambient oxygen.

The invention provides a bactericide, and belongs to the technical field of pesticides. The effective components of the bactericide provided by the invention are benzovindiflupyr and pyrimethanil, wherein the mass ratio of the benzovindiflupyr to the pyrimethanil is 1: (1-20). The benzovindiflupyr acts on a protein complex II on a mitochondrial respiration electron transfer chain of pathogenic bacteria, so that tricarboxylic acid circulation disturbance is caused, energy metabolism of the tricarboxylic acid is hindered, growth of the pathogenic bacteria is inhibited, death of the pathogenic bacteria is caused, and the purpose of preventing and treating diseases is achieved. The pyrimethanil has a unique bactericidal action mechanism, prevents pathogen infection and kills pathogens by inhibiting secretion of pathogen infection enzymes, has protection and treatment effects, and also has systemic and fumigating effects. According to the invention, the mass ratio of benzovindiflupyr to pyrimethanil is adjusted to 1: (1-20), so that the bactericide has an obvious synergistic effect, meanwhile, the resistance generated by use of a single agent is reduced, the effects of synergism and application reduction are achieved, and the pesticide cost for preventing and treating crop diseases is reduced.

The invention belongs to the technical field of skeletal muscle exercises, and discloses an application of trans-10 cis-12 conjugated linoleic acid in enhancing skeletal muscle exercise tolerance. The new application of the trans-10 cis-12 conjugated linoleic acid is provided, and the trans-10 cis-12 conjugated linoleic acid can significantly increase the running exercise time and distance of animals, increase the contraction duration of skeletal muscles of the animals and enhance the exercise tolerance of the skeletal muscles. The trans-10 cis-12 conjugated linoleic acid enhances mitochondrial respiration of the skeletal muscles of animals and oxidative metabolism related enzyme activity of the skeletal muscles, and improves skeletal muscle I-type fiber types, so that the exercise tolerance of the skeletal muscles is remarkably enhanced. The trans-10 cis-12 conjugated linoleic acid does not contain substances harmful to animals or human bodies, is low in addition amount, can be directly added into animal feed, food or medicine, has the advantages of safety, effectiveness, no toxic or side effect and the like, and has good popularization and application prospects in the aspect of enhancing exercise tolerance of the skeletal muscles.